WO2005000875A3 - Compositions and methods comprising a ligand of chemerin receptor - Google Patents

Compositions and methods comprising a ligand of chemerin receptor Download PDF

Info

Publication number
WO2005000875A3
WO2005000875A3 PCT/EP2004/006945 EP2004006945W WO2005000875A3 WO 2005000875 A3 WO2005000875 A3 WO 2005000875A3 EP 2004006945 W EP2004006945 W EP 2004006945W WO 2005000875 A3 WO2005000875 A3 WO 2005000875A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
compositions
methods
coupled receptor
protein coupled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/006945
Other languages
French (fr)
Other versions
WO2005000875A2 (en
Inventor
Valerie Wittamer
David Communi
Michel Detheux
Marc Parmentier
Cecile Loison
Fr D Ric Ooms
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ogeda SA
Original Assignee
Euroscreen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euroscreen SA filed Critical Euroscreen SA
Priority to JP2006516068A priority Critical patent/JP2007534297A/en
Priority to EP04763031.4A priority patent/EP1620463B1/en
Priority to CA2499008A priority patent/CA2499008C/en
Publication of WO2005000875A2 publication Critical patent/WO2005000875A2/en
Publication of WO2005000875A3 publication Critical patent/WO2005000875A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Psychology (AREA)

Abstract

The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screeing assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.
PCT/EP2004/006945 2003-06-25 2004-06-25 Compositions and methods comprising a ligand of chemerin receptor Ceased WO2005000875A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006516068A JP2007534297A (en) 2003-06-25 2004-06-25 Compositions and methods comprising a ligand of ChemerinR
EP04763031.4A EP1620463B1 (en) 2003-06-25 2004-06-25 Compositions and methods comprising a ligand of chemerin receptor
CA2499008A CA2499008C (en) 2003-06-25 2004-06-25 Compositions and methods comprising a ligand of chemerinr

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/603,566 US7419658B2 (en) 2001-07-09 2003-06-25 Isolated ligand of ChemerinR
US10/603,566 2003-06-25

Publications (2)

Publication Number Publication Date
WO2005000875A2 WO2005000875A2 (en) 2005-01-06
WO2005000875A3 true WO2005000875A3 (en) 2005-12-08

Family

ID=33552180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006945 Ceased WO2005000875A2 (en) 2003-06-25 2004-06-25 Compositions and methods comprising a ligand of chemerin receptor

Country Status (5)

Country Link
US (4) US7419658B2 (en)
EP (1) EP1620463B1 (en)
JP (1) JP2007534297A (en)
CA (1) CA2499008C (en)
WO (1) WO2005000875A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12534533B2 (en) 2019-10-09 2026-01-27 Ose Immunotherapeutics Anti-chemokine like receptor 1 humanized antibodies and their therapeutic applications

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101052702B (en) 2004-07-16 2013-01-09 杜邦营养生物科学有限公司 Lipolytic Enzyme and Its Application in Food Industry
JP5118018B2 (en) 2005-04-15 2013-01-16 ヒューマン マトリックス サイエンシーズ、エルエルシー Plant-derived elastin-binding protein ligand and method of use thereof
SG176477A1 (en) 2006-08-07 2011-12-29 Ironwood Pharmaceuticals Inc Indole compounds
WO2008028250A1 (en) * 2006-09-08 2008-03-13 Autogen Research Pty Ltd Therapeutic agents, targets and diagnostics
GB0705488D0 (en) * 2007-03-22 2007-05-02 Isis Innovation Treatment of inflammation and/or endotoxic shock
JP5209636B2 (en) * 2007-10-31 2013-06-12 国立大学法人神戸大学 Diabetes treatment
WO2010019811A2 (en) * 2008-08-15 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for modulators of ccrl2
AR084433A1 (en) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc FAAH INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN102772782B (en) * 2011-05-06 2015-04-22 中国科学院上海生命科学研究院 Novel lung cancer molecular marker retinoic acid receptor response protein 2
HK1202064A1 (en) * 2011-10-13 2015-09-18 托马斯．盖德克 Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions
WO2017042318A1 (en) * 2015-09-10 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Chemerin polypeptide for the treatment of cancer-induced cachexia
WO2017120589A1 (en) * 2016-01-08 2017-07-13 Washington University Compositions comprising chemerin and methods of use thereof
TWI796339B (en) * 2017-06-27 2023-03-21 大陸商尚華醫藥科技（江西）有限公司 Peptide compound, application thereof and composition containing the same
WO2019119307A1 (en) * 2017-12-20 2019-06-27 深圳先进技术研究院 Cmklr1 antagonist polypeptide, and derivative and application thereof
IL321209A (en) * 2018-04-03 2025-07-01 Ose Immunotherapeutics Anti-chemokin like receptor 1 antibodies and their therapeutic applications
US12559523B2 (en) * 2019-08-01 2026-02-24 Okyo Pharma Limited Compositions comprising chemerin analogs and methods of use
CN116217669B (en) * 2022-12-20 2026-01-30 中国人民解放军海军军医大学 A staple peptide that can enhance broad-spectrum antibacterial activity, its preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022188A1 (en) * 2000-11-20 2003-01-30 Macina Roberto A. Compositions and methods relating to colon specific genes and proteins
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948664A (en) * 1996-02-29 1999-09-07 The Regents Of The University Of California PI 3-kinase polypeptides
AU2205499A (en) * 1997-12-31 1999-07-19 Incyte Pharmaceuticals, Inc. Human regulatory proteins
CA2319089A1 (en) * 1998-04-09 1999-10-21 Genset S.A. 5' ests and encoded human proteins
DK1584683T3 (en) 1998-11-20 2007-10-29 Arena Pharm Inc Human G protein-coupled orphan receptor RUP3
AU2001271902A1 (en) 2000-07-06 2002-01-21 Deltagen, Inc. Transgenic mice containing targeted gpcr gene disruptions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022188A1 (en) * 2000-11-20 2003-01-30 Macina Roberto A. Compositions and methods relating to colon specific genes and proteins
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WITTAMER VALÉRIE ET AL: "Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids.", THE JOURNAL OF EXPERIMENTAL MEDICINE. 6 OCT 2003, vol. 198, no. 7, 6 October 2003 (2003-10-06), pages 977 - 985, XP002310262, ISSN: 0022-1007 *
WITTAMER VALÉRIE ET AL: "The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 12 MAR 2004, vol. 279, no. 11, 12 March 2004 (2004-03-12), pages 9956 - 9962, XP002310263, ISSN: 0021-9258 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12534533B2 (en) 2019-10-09 2026-01-27 Ose Immunotherapeutics Anti-chemokine like receptor 1 humanized antibodies and their therapeutic applications

Also Published As

Publication number Publication date
CA2499008A1 (en) 2005-01-06
EP1620463A2 (en) 2006-02-01
US20100009345A1 (en) 2010-01-14
US7842453B2 (en) 2010-11-30
CA2499008C (en) 2012-04-17
US20080125357A1 (en) 2008-05-29
WO2005000875A2 (en) 2005-01-06
EP1620463B1 (en) 2015-10-21
JP2007534297A (en) 2007-11-29
US7332291B2 (en) 2008-02-19
US7419658B2 (en) 2008-09-02
US20060024750A1 (en) 2006-02-02
US20040086966A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
WO2005000875A3 (en) Compositions and methods comprising a ligand of chemerin receptor
ATE309543T1 (en) NATURAL LIGAND OF GPCR CHEMR23 AND ITS USE
WO2007011907A3 (en) Alpha-synuclein antibodies and methods related thereto
CL2008000069A1 (en) METHOD OF PREPARATION OF COMPOUNDS DERIVED FROM 3,4-DIHYDROQUINOLINE.
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2005047898A3 (en) Methods and compositions for identifying therapeutic compounds
EP2154157A3 (en) FC region variants
CY1109088T1 (en) METHOD FOR PREPARATION OF SUBSTITUTED 3-ARYL-BUTYL-AMINE COMPOUNDS
EA200401198A1 (en) ANTIBODIES AGAINST αvβ6
EA200301232A1 (en) NEW ARYL SULPHONAMIDE CONNECTIONS AND THEIR APPLICATION FOR TREATMENT OF OBESITY, TYPE II DIABETES AND CENTRAL NERVOUS DISORDERS
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
WO2006110783A3 (en) Process for making (s)-pregabalin
WO2005052147A3 (en) Method of screening for a modulator of cdk4
ATE398121T1 (en) NEW SYNTHESIS OF IRBESARTAN
EP1784475A4 (en) MONITORING THE PERFORMANCE OF REFINERY RAW OIL UNITS USING IMPROVED ANALYTICAL TECHNIQUES FOR PREDICTING THE QUALITY OF RAW MATERIALS
WO2007140390A3 (en) Method for modulating hair growth
WO2006094704A3 (en) Natural ligand of g protein coupled receptor rcc356 and uses thereof
WO2002039118A8 (en) Screening methods for bone morphogenetic mimetics
BRPI0414365A (en) compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and / or diabetes.
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
ATE400273T1 (en) 1-2'-(1,4'-BIPERIDINE-1'-YL)-1-(PHENYL)-ETHYLCYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPtake MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS
EE200300092A (en) EDb-fibronectin domain receptor
WO2007047671A3 (en) Tetrahydroquinolines, synthesis thereof, and intermediates thereto
WO2006078853A3 (en) Thioredoxin interacting protein (txnip) as regulator of vascular function

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004763031

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2499008

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006516068

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004763031

Country of ref document: EP